116 related articles for article (PubMed ID: 9205743)
1. Study on the increment of the amount of gastric mucus in rats after repeated-dose administration of ebrotidine.
Romero A; Villamayor F; Palop D; Falcó J; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):455-8. PubMed ID: 9205743
[TBL] [Abstract][Full Text] [Related]
2. Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat.
Palop D; Agut J; Márquez M; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):439-46. PubMed ID: 9205740
[TBL] [Abstract][Full Text] [Related]
3. Effect of ebrotidine on ethanol-induced gastric mucosal damage in the rat. Comparative study with other H2-receptor antagonists.
Palop D; Romero A; Villamayor F; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):450-4. PubMed ID: 9205742
[TBL] [Abstract][Full Text] [Related]
4. Gastroprotective properties of ebrotidine. A review.
Slomiany BL; Piotrowski J; Slomiany A
Arzneimittelforschung; 1997 Apr; 47(4A):459-67. PubMed ID: 9205744
[TBL] [Abstract][Full Text] [Related]
5. Studies on the cytoprotective and antisecretory activity of ebrotidine. A review.
Konturek PC; Brzozowski T; Konturek SI; Márquez M; Torres J; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):578-89. PubMed ID: 9205769
[TBL] [Abstract][Full Text] [Related]
6. Involvement of endogenous nitric oxide and sulfhydryl compounds in ebrotidine-induced gastroprotection.
Palop D; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):468-71. PubMed ID: 9205745
[TBL] [Abstract][Full Text] [Related]
7. Study of the population of antral G-cells and enterochromaffin-like cells in the rat and mouse gastric mucosa after long-term treatment with ebrotidine.
Romero A; Gómez F; Villamayor F; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):520-3. PubMed ID: 9205756
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of plasma gastrin levels in rats after two months of ebrotidine administration.
Romero A; Gómez F; Villamayor F; Ballesta A; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):524-7. PubMed ID: 9205757
[TBL] [Abstract][Full Text] [Related]
9. Anti-Helicobacter pylori activities of ebrotidine. A review of biochemical and animal experimental studies and data.
Slomiany BL; Piotrowski J; Slomiany A
Arzneimittelforschung; 1997 Apr; 47(4A):475-82. PubMed ID: 9205747
[TBL] [Abstract][Full Text] [Related]
10. Ebrotidine--a new H2-receptor antagonist with mucosal strengthening activity.
Piotrowski J; Yamaki K; Morita M; Slomiany A; Slomiany BL
Biochem Int; 1992 Mar; 26(4):659-67. PubMed ID: 1351724
[TBL] [Abstract][Full Text] [Related]
11. Acute toxicity studies of ebrotidine.
Grau MT; Romero A; Villamayor F; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):490-1. PubMed ID: 9205750
[TBL] [Abstract][Full Text] [Related]
12. Gastric acid inhibitory profile of ebrotidine, a novel H2-receptor antagonist in humans.
Maczka M; Kwiecień N; Obtułowicz W; Konturek SJ; Kamiński K; Oleksy J; Gabryelewicz A; Torres J
J Physiol Pharmacol; 1992 Jun; 43(2):139-48. PubMed ID: 1356519
[TBL] [Abstract][Full Text] [Related]
13. Carcinogenicity studies on ebrotidine.
Romero A; Rives A; Grau MT; Villamayor F; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):515-9. PubMed ID: 9205755
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic study of ebrotidine administered in multiple doses to healthy volunteers for 4 days.
Frías J; Esteban C; Carcas AJ; Sánchez-García P; Albet C; Torres J; Márquez M; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):531-4. PubMed ID: 9205759
[TBL] [Abstract][Full Text] [Related]
15. Studies on the protective effect of ebrotidine on experimental ulcers induced by non-steroidal anti-inflammatory drugs in healthy volunteers.
Puscas I; Puscas C; Coltau M; Torres J; Márquez M; Herrero E; Fillat O; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):565-8. PubMed ID: 9205766
[TBL] [Abstract][Full Text] [Related]
16. Continuous intragastric pH monitoring in the evaluation of ebrotidine, cimetidine and placebo on gastric acidity in healthy volunteers.
Muñoz-Navas M; Honorato J; Reina-Ariño M; Márquez M; Herrero E; Villamayor F; Torres J; Roset PN; Fíllat O; Camps F; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):539-44. PubMed ID: 9205761
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of ebrotidine in rats and dogs.
Albet C; Pérez JA; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):483-5. PubMed ID: 9205748
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of the safety and efficacy of ebrotidine versus ranitidine and placebo in the prevention of piroxicam-induced gastroduodenal lesions.
Puscas I; Puscas C; Coltau M; Pasca R; Torres J; Márquez M; Herrero E; Fillat O; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):568-72. PubMed ID: 9205767
[TBL] [Abstract][Full Text] [Related]
19. Chronic toxicity of ebrotidine in rats and dogs.
Romero A; Grau MT; Villamayor F; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):498-504. PubMed ID: 9205752
[TBL] [Abstract][Full Text] [Related]
20. Tolerability and pharmacokinetics of ebrotidine in healthy subjects given single and repeated oral doses.
Farré M; Roset PN; Badenas JM; Ugena B; Márquez M; Albet C; Herrero E; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):528-30. PubMed ID: 9205758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
